Ascentage Pharma Group International (AAPGV) Research

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapeutic solutions for various cancers, chronic hepatitis B virus (HBV) infection, and age-related conditions, primarily within Mainland China. Its flagship product candidate, HQP1351, is a BCR-ABL inhibitor specifically designed to target BCR-ABL1 mutants, notably those harboring the T315I mutation. The company's extensive pipeline further comprises: APG-2575, an orally administered, selective Bcl-2 inhibitor for hematologic malignancies and solid tumors. APG-115, an oral small-molecule inhibitor of MDM2-p53 protein-protein interactions, aimed at treating solid tumors and hematological cancers. APG-1252, a small-molecule drug engineered to restore apoptosis through dual inhibition of Bcl-2 and Bcl-xL proteins, indicated for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. APG-2449, an oral inhibitor targeting FAK, ROS1, and ALK kinases. APG-5918, an orally available and selective embryonic ectoderm development inhibitor. APG-265, an MDM2 protein degrader. UBX1967/1325, which are also Bcl-2 inhibitors. Beyond its pharmaceutical development, Ascentage Pharma's operations encompass medical research and development, clinical trial management and execution, venture capital investments, rental services, and the promotion of science and technology. The company cultivates collaborative partnerships with various biotechnology and pharmaceutical enterprises, as well as academic research institutions. Established in 2009, Ascentage Pharma Group International is headquartered in Suzhou, China.

Open Ascentage Pharma Group International (AAPGV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.